Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Gene-Sequencing Company Illumina to Sell Cancer Test Developer

The move came two days after a court upheld the Federal Trade Commission’s challenge to the deal on antitrust grounds.

Nicole Sperling
Author: Nicole Sperling

Written by

Nicole Sperling

in

Antitrust Laws and Competition Issues, Decisions and Verdicts, European Union, Federal Trade Commission, Genetic Engineering, Grail Inc, Illumina Inc, Mergers, Acquisitions and Divestitures, Regulation and Deregulation of Industry, Tests (Medical)
←Florida Republican Party Suspends Chairman, Demands Resignation Amid Rape Investigation
Trump Says Nevada Fake Electors Treated ‘Unfairly’ During Rally In Reno→

More posts

  • Protesters, leaders push back against DHS over Newark detention facility conditions

  • Goldman and Lander spar hard over Israel

  • Snowflake climbs after Q1 results top expectations, guidance gets a boost

  • Synopsys drops despite better than expected Q2 results, big boost to full-year guidance

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube